Correction: Pik3ca c2 domain deletions hyperactivate phosphoinositide 3-kinase (pi3k), generate oncogene dependence, and are exquisitely sensitive to pi3ka inhibitors(Clin Cancer Res (2018) 24 (1426–35)DOI: 10.1158/1078-0432.CCR-17-2141);PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors

Clinical Cancer Research

Volumn 24, Issue 6, 2018, Pages 1426-1435

  Croessmann, Sarah ^a   Sheehan, Jonathan H ^a,b   Lee, Kyung min ^a   Sliwoski, Gregory ^c   He, Jie ^d   Nagy, Rebecca ^e   Riddle, David ^a   Mayer, Ingrid A ^a,f   Balko, Justin M ^a,f   Lanman, Richard ^e   Miller, Vincent A ^d   Cantley, Lewis C ^g   Meiler, Jens ^b,c   Arteaga, Carlos L ^a,b,f  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d FOUNDATION MEDICINE   (United States)

^e Guardant Health   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; AMINO ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 ALPHA; PROTEIN P85; PROTEIN P85 ALPHA; PROTEIN S6; UNCLASSIFIED DRUG;

ARTICLE; C2 DOMAIN; CELL TRANSFORMATION; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MCF-10A CELL LINE; ONCOGENE; PHENOTYPE; PI3K/AKT SIGNALING; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WILD TYPE;

EID: 85048124207     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-18-4269     Document Type: Erratum

References (28)

1. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015;15:7–24.
2. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
3. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 2007;104: 5569–74.
4. Engelman JA.Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550–62.
5. Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, et al. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell 2013;23:796–810.
6. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007;318:1744–8.
7. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A 2012;109:15259–64.
8. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010;70:5674–8.
9. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65:10992–1000.
10. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011;17:1116–20.
11. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17:1331–40.
12. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A 2009;106:2835–40.
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.
14. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10 1.
15. Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, et al. Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2þ breast cancer. Cancer Res 2017; 77:3280–92.
16. Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A phase Ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ERþ/HER2- metastatic breast cancer. Clin Cancer Res 2017;23:26–34.
17. Bender BJ, Cisneros A III, Duran AM, Finn JA, Fu D, Lokits AD, et al. Protocols for molecular modeling with Rosetta3 and RosettaScripts. Biochemistry 2016;55:4748–63.
18. Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang CH, et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A 2009; 106:16996–7001.
19. Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 2010;9:596–600.
20. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562–7.
21. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005; 102:802–7.
22. Mukohara T.PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer 2015;7:111–23.
23. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 2007;32:342–9.
24. Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM. Structural effects of oncogenic PI3Kalpha mutations. Curr Top Microbiol Immunol 2010;347:43–53.
25. Shekar SC, Wu H, Fu Z, Yip SC, Nagajyothi, Cahill SM, et al. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 2005;280:27850–5.
26. 0-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998;18:1379–87.
27. Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC, et al. Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci U S A 2006;103:12093–7.
28. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002;22:965–77.